LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material Kurvelo™

Levonorgestrel and Ethinyl Estradiol Tablets USP

0.15 mg/30 mcg

Manufacturer Lupin Limited

Pithampur (M.P.) – 454 775

INDIA.

Distributor Lupin Pharmaceuticals, Inc.

111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202

United States

Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification

Fire and Explosion

Expected to be non-combustible.

Health

Kurvelo is contraindicated in females who are known to have the following conditions:

- A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:
- Smoke, if over age 35
- Have current or history of deep vein thrombosis or pulmonary embolism.
- Have cerebrovascular disease.
- Have coronary artery disease.
- Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation).
- Have inherited or acquired hypercoagulopathies.
- Have uncontrolled hypertension or hypertension with vascular disease.
- Have diabetes mellitus and are over age 35, diabetes mellitus with hypertension or vascular disease or other end-organ damage, or diabetes mellitus of >20 years duration.
 - Have headaches with focal neurological symptoms, migraine headaches with aura, or over age 35 with any migraine headaches.
- Current or history of breast cancer or other estrogen- or progestin-sensitive cancer.
- Liver tumors, acute viral hepatitis, or severe (decompensated) cirrhosis.

SDS : 063/03 Page 1 of 5

- Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations.
- Undiagnosed abnormal uterine bleeding.
- Pregnancy, because there is no reason to use COCs during pregnancy.

Environment

No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

IngredientsCASLevonorgestrel USP797-63-7Ethinyl Estradiol USP57-63-6

Section 4: First-Aid Measures

Section 4, First-aid measures

Ingestion If conscious, give water to drink and induce vomiting. Do not attempt to

give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical

attention.

Inhalation Move individual to fresh air. Obtain medical attention if breathing

difficulty occurs. If not breathing, provide artificial respiration

assistance.

Skin Contact Remove contaminated clothing and flush exposed area with large

amounts of water. Wash all exposed areas of skin with plenty of soap

and water. Obtain medical attention if skin reaction occurs.

Eye Contact Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance,

refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

OVERDOSAGE There have been no reports of serious adverse outcomes from

overdose of COCs, including ingestion by children. Overdose may

cause uterine bleeding in females and nausea.

Section 5: Fire-Fighting Measures

Section 5, Fire-fighting measures

Fire and Explosion Hazards Assume that this product is capable of sustaining combustion.

SDS : 063/03 Page 2 of 5

Extinguishing Media Water spray, carbon dioxide, dry chemical powder or appropriate

foam.

Special Firefighting Procedures For single units (packages): No special requirements needed.

For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended

for firefighters.

Hazardous Combustion Products Hazardous combustion or decomposition products are expected

when the product is exposed to fire.

Section 6: Accidental Release Measures

Section 6, Accidental release measures

Personal Precautions Wear protective clothing and equipment consistent with the degree of

hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways,

sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labeled container for

recovery or disposal.

Section 7: Handling and Storage

Section 7, Handling and storage

Handling No special control measures required for the normal handling of this

product.

Normal room ventilation is expected to be adequate for routine

handling of this product.

Storage Store at 25° C (77° F); excursions permitted to 15° to 30° C

(59° to 86° F) [see USP Controlled Room Temperature].

Section 8: Exposure Controls/Personal Protection

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form HOW SUPPLIED

Kurvelo Tablets (levonorgestrel and ethinyl estradiol tablets USP) (3×28) are available in packages of 3 blisters, each containing

28 tablets as follows:

Each blister strip contains 21 light orange tablets, each containing of 0.15 mg levonorgestrel and 30 mcg ethinyl estradiol, debossed

with "LU" on one side and "U31" on the other side.

SDS : 063/03 Page 3 of 5

7 inert pink, round, biconvex tablets, debossed with "LU" on one side and "U32" on the other side.

They are supplied as follows:

Kurvelo tablets are available in a blister (NDC 68180-844-71) containing 28 tablets, such 3 blisters are packed in a carton (NDC 68180-844-73).

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information

None

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated

IMDG Proper shipping Name:N/AIMDG UN/ID No:N/AIMDG Hazard Class:N/AIMDG Flash Point:N/AIMDG Label:N/A

DOT - Not Regulated

DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A

SDS : 063/03 Page 4 of 5

DOT Packing Group : N/A DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.

SDS : 063/03 Page 5 of 5